Japan multicenter prospective study: FDG-PET/CT as imaging biomarker to evaluate the response of Axitinib for Sunitinib failed metastatic renal cell carcinoma patients. - FDG-PET/CT as imaging biomarker to evaluate the response of Axitinib for Sunitinib failed mRCC patients.

Yokohama City University0 个研究点目标入组 50 人开始时间: 2013年12月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet any of the following are excluded from the study. (1)Poorly-controlled diabetes mellitus (fasting blood glucose  150 g/dL) (2)History of organ transplantation (including bone marrow transplantation) (3)History of malignancy except: (i)Curatively treated intraepithelial cervical cancer, basal cell carcinoma, superficial bladder cancer (Ta, Tis and T1). (ii)Patients who had been disease free more for than 3 years after curative therapy (4)Central nervous system metastases. However, patients who remain asymptomatic, have no new or enlarging lesion in the CNS within 6 months of enrollment in this study (5)History of cardiac infarction, unstable angina, congestive heart failure, or symptomatic peripheral vascular disease within 12 months of enrollment (6)History of cerebrovascular disorder including transient ischemic attack (TIA) (7)Pregnant and/or nursing woman, possibility of pregnancy

发起方